Euroapi SA (STU:940)

Full Year 2025 Euroapi SA Earnings Call Transcript

Mar 4, 2026 / 07:30 AM GMT

Release Date Price: €1.44 (-25.80%)

Transcript

Key Points

Positve

Euroapi SA (EAPIF) achieved a 31% increase in core EBITDA, reaching €66.2 million, with a margin improvement to 7.8% from 5.5% in 2024.
The company successfully reduced external expenses and personnel costs, demonstrating strong financial discipline.
Euroapi SA (EAPIF) maintained strict working capital discipline, improving inventory management and reducing trade receivables.
The company achieved significant progress in carbon emission reduction, aligning with the Paris Agreement, and exceeded its target for Scope 3 emissions.
Euroapi SA (EAPIF) gained 31 new clients in 2025, with sales to non-Sanofi clients increasing by 9.7%.

Negative

Net sales decreased by 7% to €848.2 million in 2025, with a significant decline in sales to Sanofi by 26.4%.
The company faced challenges from increased competition, particularly from low-cost Asian players, impacting pricing and volumes.
Euroapi SA (EAPIF) experienced a stable injury rate in 2025, indicating ongoing safety challenges despite efforts to improve.
The discontinuation of the vitamin B12 project led to an asset impairment of €77.8 million, reflecting a reassessment of its economic potential.
The company anticipates a 10% decrease in net sales for 2026 due to portfolio rationalization and continued decline in sales to Sanofi.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

EAPI.PA - Euroapi SA
Full Year 2025 Euroapi SA Earnings Call
Mar 04, 2026 / 07:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, welcome to the OOAP 2025 full year results. The call will be structured in two parts. First, a presentation by the OOAP Group management team represented by David Senol, CEO, and Olivier Faliu, CFO. Afterwards there will be a Q&A session. During this session, You may ask a question in two ways by submitting a written question in the box below the player, or by joining the conference call and dial 5 on your telephone keypad to enter the queue. I will now hand over to Sophie Palier, head of financing, treasury, and shareholder engagement. Madam, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
----------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.